Jill Meyer, MD
Nephrology · Chula Vista, CANPI 1255394789
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,622 of the $5,255 with a category attached, or 88.0%. It is spread thinly across 32 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,883 and has fallen 95.6% since, to $84 in 2025.
Across 163 payments — averaging $32.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- Aurinia Pharma U.S., Inc.$656
- AstraZeneca$621
- Nxstage Medical, Inc.$244
- OPKO Pharmaceuticals, LLC$234
- Bayer$222
- plus $2K from 26 others
Across 699 payments — averaging $2607.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$780K
- Bayer$362K
- Akebia Therapeutics Inc$289K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$137K
- Fresenius USA Marketing, Inc.$120K
- Ardelyx, Inc.$43K
- plus $91K from 5 others
What the payments were for
- Travel & lodging$59911%
- Food & beverage$4,62288%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $1,106 |
| Aurinia Pharma U.S., Inc. | 10 | $656 |
| AstraZeneca(2 entities) | 21 | $621 |
| Nxstage Medical, Inc. | 4 | $244 |
| OPKO Pharmaceuticals, LLC | 10 | $234 |
| Bayer | 8 | $222 |
| Akebia Therapeutics Inc | 6 | $215 |
| Otsuka America Pharmaceutical, Inc. | 10 | $207 |
| Mallinckrodt Enterprises LLC | 8 | $199 |
| Calliditas Therapeutics US Inc. | 3 | $195 |
| Fresenius USA Marketing, Inc. | 10 | $184 |
| Amgen(2 entities) | 10 | $182 |
| Vifor Pharma, Inc. | 9 | $181 |
| GSK | 4 | $147 |
| Novo Nordisk | 7 | $135 |
| Daiichi Sankyo Inc. | 6 | $104 |
| Cumberland Pharmaceuticals, Inc. | 4 | $60 |
| Shire North American Group Inc | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Lilly USA, LLC | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| AMAG Pharmaceuticals, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Dexcom, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Veloxis Pharmaceuticals, Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $11 |
| Travere Therapeutics, Inc. | 3 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,255 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 281 | $310,650 |
| OzempicSemaglutide | 213 | $288,308 |
| LokelmaSodium Zirconium Cyclosilicate | 249 | $203,824 |
| JardianceEmpagliflozin | 181 | $195,418 |
| VelphoroSucroferric Oxyhydroxide | 38 | $167,167 |
| TrulicityDulaglutide | 82 | $134,546 |
| RybelsusSemaglutide | 48 | $87,934 |
| VeltassaPatiromer Calcium Sorbitex | 72 | $79,134 |
| Sevelamer Carbonate | 100 | $45,789 |
| JanuviaSitagliptin Phosphate | 39 | $42,147 |
| ProcritEpoetin Alfa | 41 | $28,280 |
| KerendiaFinerenone | 28 | $27,331 |
| DapagliflozinDapagliflozin Propanediol | 36 | $18,329 |
| EliquisApixaban | 13 | $18,001 |
| InvokanaCanagliflozin | 12 | $13,299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $621 | $514,474530 claims |
| Novo NordiskOzempic, Rybelsus | $135 | $376,242261 claims |
| Boehringer IngelheimJardiance, Tradjenta | $17 | $205,791193 claims |
| Fresenius USA Marketing, Inc.Velphoro | $184 | $167,16738 claims |
| Lilly USA, LLCTrulicity | $34 | $134,54682 claims |
| MerckJanuvia | $1,106 | $42,14739 claims |
| Johnson & JohnsonProcrit, Invokana | $20 | $41,57853 claims |
| BayerKerendia | $222 | $27,33128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,341 nephrology providers in California.
Other nephrology in Chula Vista
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.